Mount Sinai School of Medicine, Department of Medicine, The Global Health and Emerging Pathogens Institute, New York, New York 10029, USA.
J Virol. 2010 Sep;84(18):9613-7. doi: 10.1128/JVI.02630-09. Epub 2010 Jun 30.
Multiple APOBEC3 proteins are expressed in HIV-1 target cells, but their individual contributions to viral suppression when expressed at endogenous levels remain largely unknown. We used an HIV NL4-3 mutant that selectively counteracts APOBEC3G (A3G) but not APOBEC3F (A3F) to dissect the relative contribution of A3F to the inhibition of HIV-1 replication in primary human lymphocytes (peripheral blood mononuclear cells [PBMCs]). This HIV Vif mutant replicated similarly to wild-type virus in PBMCs, suggesting that the effect of A3F on HIV restriction in these cells is limited. The different A3F variants found in PMBC donors displayed either comparable activity or less activity than wild-type A3F. Lastly, the endogenous A3F mRNA and protein expression levels in PBMCs were considerably lower than those of A3G. Our results suggest that A3F neutralization is dispensable for HIV-1 replication in primary human T-lymphocytes.
多种 APOBEC3 蛋白在 HIV-1 靶细胞中表达,但它们在表达内源水平时对病毒抑制的个体贡献在很大程度上仍不清楚。我们使用了一种 HIV NL4-3 突变体,该突变体能选择性地抵抗 APOBEC3G(A3G)而不是 APOBEC3F(A3F),从而剖析 A3F 对原发性人淋巴细胞(外周血单核细胞[PBMC])中 HIV-1 复制的抑制作用。这种 HIV Vif 突变体在 PBMC 中的复制与野生型病毒相似,表明 A3F 对这些细胞中 HIV 限制的作用有限。在 PMBC 供体中发现的不同 A3F 变体表现出与野生型 A3F 相当的活性或较低的活性。最后,PBMC 中内源性 A3F mRNA 和蛋白表达水平明显低于 A3G。我们的研究结果表明,A3F 中和对于原发性人 T 淋巴细胞中的 HIV-1 复制是可有可无的。